393 related articles for article (PubMed ID: 26084637)
1. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
Horneff G
Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637
[TBL] [Abstract][Full Text] [Related]
2. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
4. Biologic-associated infections in pediatric rheumatology.
Horneff G
Curr Rheumatol Rep; 2015 Nov; 17(11):66. PubMed ID: 26385753
[TBL] [Abstract][Full Text] [Related]
5. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].
Horneff G
Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
7. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
Diener C; Horneff G
Expert Opin Drug Saf; 2019 Aug; 18(8):719-732. PubMed ID: 31204508
[No Abstract] [Full Text] [Related]
8. [Biological therapy treatment of juvenile idiopathic arthritis].
Herlin T
Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
[TBL] [Abstract][Full Text] [Related]
11. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
12. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.
Carrasco R; Smith JA; Lovell D
Paediatr Drugs; 2004; 6(3):137-46. PubMed ID: 15170361
[TBL] [Abstract][Full Text] [Related]
13. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
14. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
Beresford MW; Baildam EM
Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
[TBL] [Abstract][Full Text] [Related]
15. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
[TBL] [Abstract][Full Text] [Related]
16. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
17. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].
Horneff G
Z Rheumatol; 2006 Mar; 65(2):152-6, 158. PubMed ID: 16372138
[TBL] [Abstract][Full Text] [Related]
18. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
[TBL] [Abstract][Full Text] [Related]
19. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
